This satellite symposium took place on 4th September 2016 as a part of the European Respiratory Society (ERS) International Congress in London, UK
Chairperson: Helen Reddel1
Speakers: Kai-Michael Beeh,2 John Haughney,3 Sinthia Bosnic-Anticevich,4 Henry Chrystyn5
1. Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
2. Insaf Respiratory Research Institute, Wiesbaden, Germany
3. Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
4. School of Medical Sciences, University of Sydney, Sydney, Australia
5. Inhalation Consultancy Limited, Leeds, UK; Faculty of Health and Human Sciences,
University of Plymouth, Plymouth, UK; Research in Real Life (RiRL), Cambridge, UK
Disclosure: Prof Reddel has received honoraria for advisory board membership and provision of independent medical education from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Merck Mundipharma, and Teva Pharmaceuticals, and research grants from AstraZeneca and GSK. Dr Beeh is employed by an institution that has received honoraria for consultancy and speaking services from Ablynx, Almirall, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Chiesi, Cytos, ERT, GSK, Mundipharma, Novartis, Pohl Boskamp, Takeda, and Zentiva, and compensation for the design and performance of clinical trials from Almirall, Altana/Nycomed, AstraZeneca, Boehringer, Cytos, GSK, Infinity, Medapharma, Merck Sharp & Dohme, Mundipharma, Novartis, Parexel, Pearl Therapeutics, Pfizer, Teva Pharmaceuticals, Sterna, and Zentiva. Dr Haughney has received fees for consulting and speaking services, and significant support for his department, research, travel, and accommodation from Almirall, Boehringer Ingelheim, Chiesi, AstraZeneca, GSK, Merck Sharp & Dohme, Mundipharma, Napp Pharmaceuticals, Novartis, Orion Pharma, Pfizer, Sanofi-Aventis, Teva Pharmaceuticals, and Zentiva. Prof Bosnic-Anticevich has received honoraria for consultancy services from AstraZeneca, GSK, Mundipharma, and Teva Pharmaceuticals. Prof Chrystyn has received sponsorship to carry out studies and honoraria for consultancy and speaking services from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Innovata Biomed, Meda, Mundipharma, Napp Pharmaceuticals, Norpharma, Orion Pharma, Sanofi-Aventis, Teva Pharmaceuticals, Trudell Medical International, UCB, and Zentiva.
Acknowledgements: Writing assistance was provided by Dr Blair Hesp, CMPP, of ApotheCom.
Support: The symposium was sponsored by Teva Pharmaceuticals. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Teva Pharmaceuticals.
Citation: EMJ Respir. 2016;4:43-50.
Prof Helen Reddel opened the symposium by discussing the need to examine the modifiable nonpharmacological factors in the treatment of asthma and chronic obstructive pulmonary disease (COPD) that can be addressed to improve clinical outcomes. Dr Kai-Michael Beeh set the scene and discussed the need to review patient behaviour and drug delivery mechanisms to improve outcomes for patients with asthma and COPD. Dr John Haughney then discussed how patient preferences for inhalers can impact real-world outcomes. Prof Sinthia Bosnic-Anticevich outlined the challenges in learning and maintaining correct inhaler technique, while Prof Henry Chrystyn highlighted how inhaler design can help minimise the impact of inhaler errors on clinical outcomes. Prof Helen Reddel closed the session by bridging the gap between guidelines and clinical care, describing ways to incorporate regular checking and training of inhaler skills into a range of settings.
The meeting objectives were to look beyond drugs to the role of devices in optimising asthma and COPD management, to understand the impact of inhaler technique on treatment efficacy, to review how patient perspectives about their inhaler can impact on clinical outcomes, and to discuss how to implement current clinical guidelines on inhaler technique in day-to-day clinical care.